Center for Molecular Discovery to market technologies

Larry Sklar
UNMCMD principal investigator Larry Sklar

HSC NewsBeat
July 16, 2014

Accelera Diagnostics and STC.UNM recently announced a limited exclusive option agreement for a portfolio of technologies developed at UNM’s Center for Molecular Discovery (CMD), including compounds, repurposed drugs, devices and highly sophisticated methods for analysis and characterization used for the discovery of new treatments for cancer and other diseases.

The inventions were developed by a collaborative group of researchers at the UNM Health Sciences Center (HSC), including Drs. Larry Sklar, Bruce Edwards, Angela Wandinger-Ness, Alexandre Chigaev, and Richard Larson from the Department of Pathology; Dr. Eric Prossnitz from the Department of Cell Biology and Physiology; Dr. Todd Thompson from the Department of Pharmaceutical Sciences; and other UNM researchers.

Sklar, a Distinguished Professor of Pathology, the center’s director, and a UNM Innovation Fellow for his many inventions with high commercial impact, is looking forward to working with Accelera. “The investors and the inventors contributing to this portfolio have a shared vision for making an impact by working together to save lives,” he says. Read more.

University of New Mexico flow cytometry research center